{
    "Rank": 990,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00140478",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "04-249"
                },
                "Organization": {
                    "OrgFullName": "Dana-Farber Cancer Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Mifepristone (RU-486) in Androgen Independent Prostate Cancer",
                "OfficialTitle": "A Phase II Study of Mifepristone (RU-486) in Androgen Independent Prostate Cancer With Correlative Assessment of Androgen Receptor Co-Repressor Proteins"
            },
            "StatusModule": {
                "StatusVerifiedDate": "December 2009",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "February 2005"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 2006",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "January 2008",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "August 30, 2005",
                "StudyFirstSubmitQCDate": "August 30, 2005",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 1, 2005",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "December 7, 2009",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "December 9, 2009",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyOldNameTitle": "Mary-Ellen Taplin",
                    "ResponsiblePartyOldOrganization": "Dana-Farber Cancer Institute"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Dana-Farber Cancer Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Beth Israel Deaconess Medical Center",
                            "CollaboratorClass": "OTHER"
                        },
                        {
                            "CollaboratorName": "Massachusetts General Hospital",
                            "CollaboratorClass": "OTHER"
                        },
                        {
                            "CollaboratorName": "Brigham and Women's Hospital",
                            "CollaboratorClass": "OTHER"
                        },
                        {
                            "CollaboratorName": "Georgetown University",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {},
            "DescriptionModule": {
                "BriefSummary": "The purpose of this study is to determine the effects (good and bad) that mifepristone has on patients with androgen independent prostate cancer.",
                "DetailedDescription": "Patients will receive mifepristone, 200mg orally once a day. One treatment cycle is 28 days long. Patients will remain on treatment unless their cancer gets worse or they develop intolerable side effects.\n\nAt the end of each cycle a physical examination, routine blood tests, and hormone levels will be performed.\n\nAfter every 3 cycles, one or more of the following will be performed: bone scan, chest x-ray, CT scan or MRI."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Prostate Cancer",
                        "Adenocarcinoma of Prostate"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Androgen Independent Prostate Cancer",
                        "Prostate Cancer",
                        "Mifepristone",
                        "RU-486"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Non-Randomized",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "48",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Mifepristone",
                            "InterventionDescription": "200mg orally once daily",
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "RU-486"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "To determine the therapeutic efficacy of mifepristone in patients with androgen independent prostate cancer",
                            "PrimaryOutcomeTimeFrame": "2 years"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "To determine the duration of response, time to disease progression and safety of mifepristone in patients with androgen independent prostate cancer"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nHistologic documentation of adenocarcinoma of the prostate\nBone metastasis(es) by bone scan or cat scan\nClinical, biochemical, or radiographic progression after primary androgen ablation with either orchiectomy or gonadotropin releasing hormone analog therapy.\nOne prior chemotherapy treatment is allowed.\n> 3 weeks since major surgery\n> 4 weeks since radiotherapy\n> 8 weeks since prior strontium-89 or samarium 153\nECOG performance status 0 or 1\nAbsolute neutrophil count (ANC) > 1,500/ul\nPlatelets > 100,000/ul\nBilirubin < 1.5 x upper limit of normal (ULN)\nAST or ALT < 3 x ULN\nCreatinine < 1.5 x ULN\nElectrolytes within 10% of normal range\nSerum testosterone < 50ng/dL\nProstate-specific antigen (PSA) > 5.0ng/ml\n\nExclusion Criteria:\n\nConcomitant therapy with corticosteroids\nChemotherapy within 28 days\nCurrently active second malignancy other than non-melanoma skin cancer\nBaseline adrenal insufficiency requiring long-term steroids",
                "HealthyVolunteers": "No",
                "Gender": "Male",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Mary-Ellen Taplin, MD",
                            "OverallOfficialAffiliation": "Dana-Farber Cancer Institute",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Georgetown University",
                            "LocationCity": "Washington",
                            "LocationState": "District of Columbia",
                            "LocationZip": "20057",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Beth Israel Deaconess Medical Center",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02115",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Dana-Farber Cancer Institute",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02115",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Massachusetts General Hospital",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02115",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000011471",
                            "ConditionMeshTerm": "Prostatic Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000005834",
                            "ConditionAncestorTerm": "Genital Neoplasms, Male"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005832",
                            "ConditionAncestorTerm": "Genital Diseases, Male"
                        },
                        {
                            "ConditionAncestorId": "D000091662",
                            "ConditionAncestorTerm": "Genital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000011469",
                            "ConditionAncestorTerm": "Prostatic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000052801",
                            "ConditionAncestorTerm": "Male Urogenital Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M14025",
                            "ConditionBrowseLeafName": "Prostatic Neoplasms",
                            "ConditionBrowseLeafAsFound": "Prostate Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M3275",
                            "ConditionBrowseLeafName": "Adenocarcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8636",
                            "ConditionBrowseLeafName": "Genital Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2877",
                            "ConditionBrowseLeafName": "Genital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8634",
                            "ConditionBrowseLeafName": "Genital Diseases, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14023",
                            "ConditionBrowseLeafName": "Prostatic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26785",
                            "ConditionBrowseLeafName": "Male Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T3215",
                            "ConditionBrowseLeafName": "Kennedy Disease",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000015735",
                            "InterventionMeshTerm": "Mifepristone"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000021",
                            "InterventionAncestorTerm": "Abortifacient Agents, Steroidal"
                        },
                        {
                            "InterventionAncestorId": "D000000019",
                            "InterventionAncestorTerm": "Abortifacient Agents"
                        },
                        {
                            "InterventionAncestorId": "D000012102",
                            "InterventionAncestorTerm": "Reproductive Control Agents"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000003280",
                            "InterventionAncestorTerm": "Contraceptives, Oral, Synthetic"
                        },
                        {
                            "InterventionAncestorId": "D000003276",
                            "InterventionAncestorTerm": "Contraceptives, Oral"
                        },
                        {
                            "InterventionAncestorId": "D000003271",
                            "InterventionAncestorTerm": "Contraceptive Agents, Female"
                        },
                        {
                            "InterventionAncestorId": "D000003270",
                            "InterventionAncestorTerm": "Contraceptive Agents"
                        },
                        {
                            "InterventionAncestorId": "D000003283",
                            "InterventionAncestorTerm": "Contraceptives, Postcoital, Synthetic"
                        },
                        {
                            "InterventionAncestorId": "D000003281",
                            "InterventionAncestorTerm": "Contraceptives, Postcoital"
                        },
                        {
                            "InterventionAncestorId": "D000006727",
                            "InterventionAncestorTerm": "Hormone Antagonists"
                        },
                        {
                            "InterventionAncestorId": "D000006730",
                            "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                        },
                        {
                            "InterventionAncestorId": "D000008186",
                            "InterventionAncestorTerm": "Luteolytic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000080066",
                            "InterventionAncestorTerm": "Contraceptive Agents, Hormonal"
                        },
                        {
                            "InterventionAncestorId": "D000008600",
                            "InterventionAncestorTerm": "Menstruation-Inducing Agents"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M3749",
                            "InterventionBrowseLeafName": "Androgens",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M17990",
                            "InterventionBrowseLeafName": "Mifepristone",
                            "InterventionBrowseLeafAsFound": "Attempt",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M6184",
                            "InterventionBrowseLeafName": "Contraceptive Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M6190",
                            "InterventionBrowseLeafName": "Contraceptives, Oral",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M6195",
                            "InterventionBrowseLeafName": "Contraceptives, Postcoital",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9479",
                            "InterventionBrowseLeafName": "Hormones",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9478",
                            "InterventionBrowseLeafName": "Hormone Antagonists",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M2116",
                            "InterventionBrowseLeafName": "Contraceptive Agents, Hormonal",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Repr",
                            "InterventionBrowseBranchName": "Reproductive Control Agents"
                        }
                    ]
                }
            }
        }
    }
}